Miller William H, Brosnan M Julia, Graham Delyth, Nicol Campbell G, Morecroft Ian, Channon Keith M, Danilov Sergei M, Reynolds Paul N, Baker Andrew H, Dominiczak Anna F
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G11 6NT, Scotland, UK.
Mol Ther. 2005 Aug;12(2):321-7. doi: 10.1016/j.ymthe.2005.02.025.
Local adenoviral (Ad)-mediated gene transfer to the carotid artery of the stroke-prone spontaneously hypertensive rat (SHRSP) is successful in improving endothelial function. Here we explored the potential of systemic delivery of Ad encoding endothelial nitric oxide synthase (AdeNOS) to prevent elevation of blood pressure in the SHRSP using both nontargeted and vector targeting approaches. Systemic administration of nontargeted AdeNOS failed to modify the rise in blood pressure in SHRSP when administered during the 12th week of age (n = 5, P = 0.088, F = 3.0), an effect likely to result from sequestration of Ad by the liver. Rerouting Ad transduction using a bispecific antibody (anti-ACE/anti-Ad capsid, Fab9B9) that blocks Ad binding to the coxsackie and adenovirus receptor and simultaneously retargets AdeNOS to the angiotensin-converting enzyme resulted in efficient eNOS overexpression in the lung vasculature and a sustained hypotensive effect (n = 5, P = 0.007, F = 7.9). This study highlights the importance of vector targeting to achieve therapeutic gain and represents the first such study in cardiovascular gene therapy.
局部腺病毒(Ad)介导的基因转移至易中风自发性高血压大鼠(SHRSP)的颈动脉,成功改善了内皮功能。在此,我们探索了采用非靶向和载体靶向方法全身递送编码内皮型一氧化氮合酶(AdeNOS)的腺病毒,以预防SHRSP血压升高的潜力。在12周龄时给予非靶向AdeNOS全身给药未能改变SHRSP血压的升高(n = 5,P = 0.088,F = 3.0),这种效应可能是由于肝脏对腺病毒的隔离所致。使用双特异性抗体(抗ACE/抗Ad衣壳,Fab9B9)重新引导腺病毒转导,该抗体可阻断腺病毒与柯萨奇病毒和腺病毒受体的结合,并同时将AdeNOS重新靶向至血管紧张素转换酶,导致肺血管中eNOS有效过表达,并产生持续的降压作用(n = 5,P = 0.007,F = 7.9)。本研究强调了载体靶向以实现治疗效果的重要性,并且代表了心血管基因治疗中的首个此类研究。